Meeting Mic
In this episode of Meeting Mic, we bring you the highlights and insights from the San Antonio Breast Cancer Symposium 2025, as well as Healio’s top headlines from the meeting. Amy Comander, MD, DipABLM, FACLM, MSCP, highlights presentations at this year’s meeting. :26 Jun J. Mao, MD, MSCE, discusses results from a phase 2 trial surrounding acupuncture for breast cancer. 1:50 Amanda M. Woodworth, MD, FACS, CPE, describes a digital toolkit for advancing risk-informed breast cancer screening. 4:41 Read the full coverage here: Disclosures: Comander reports no relevant financial...
info_outlineMeeting Mic
In this episode of Meeting Mic, we bring you pearls and perspectives from the 2025 Neuroscience Educational Institute (NEI) Annual Congress. David W. Goodman, MD, LFAPA, discusses his presentation about ADHD in adults including diagnosis, treatment and the current challenges. :22 Katherine Dahlsgaard, PhD, ABPP, talks about her presentations on behavioral interventions for sleepy adolescents as well as the challenges physicians face in prescribing psychiatric medicines. 5:43 Kari L. Franson, PharmD, PhD, BCPP, FNAP, highlights her presentations on the current status of prescription digital...
info_outlineMeeting Mic
In this episode of Meeting Mic, we bring you pearls and perspectives from the 2025 Gerontological Advanced Practice Nurses Association (GAPNA) Annual Conference. Kimberly Posey, AGPCNP-BC, DNP, PhD, GS-C, discusses the purpose for the meeting, and highlights from this year’s conference. :19 George Peraza-Smith, DNP, A-GNP-C, GNP-BC, GS-C, CNE, FAANP, immediate past president of GAPNA, provides an overview on popular presentations from the meeting, and goals for the future of the organization. 12:25 Disclosures: Healio was unable to confirm relevant disclosures at the time of publication.
info_outlineMeeting Mic
In this episode of Meeting Mic, we bring you pearls and perspectives from the 2025 American Society of Retina Specialists annual meeting, as well as Healio’s top headlines from the meeting. Andrew G. Lee, MD, discusses when retina experts should refer patients to a neuro-ophthalmologist. 0:29 Sunir J. Garg, MD, FACS, FASRS, provides an overview of lessons learned from two complex surgical cases. 1:52 Sunir J. Garg, MD, FACS, FASRS, overviewed key findings from the Global Trends in Retina Survey. 5:16 Michael O’Rouke talks collaborating with Boehringer Ingelheim to develop...
info_outlineMeeting Mic
In this episode of Meeting Mic, we bring you pearls and perspectives from the 2025 ASCO Annual Meeting, as well as Healio’s top headlines from the meeting. Chinmay Jani, MD, discusses findings highlighting how alcohol-related cancer mortality has risen sharply over the past few decades. :19 Rachel I. Vogel, PhD, provides and overview on factors contributing to the time burden cancer care places on patients. 3:02 Alexander D. Sherry, MD, discusses how improvements in OS or quality of life after phase 3 oncology trials are based on improvements in unvalidated alternative...
info_outlineMeeting Mic
In this episode of Meeting Mic, we bring you pearls and perspectives from the 2025 American Academy of Neurology Annual Meeting. Mary A. O'Neal, MD, FAAN, and Ratna K. Bhavaraju-Sanka, MD, FAAN, discuss their efforts to address the lack of access to neurological care by partnering with primary care. :34 Merit E. Cudkowicz, MD, MSc, FAAN, speaks with Healio about being honored The American Academy of Neurology’s Lifetime Achievement Award for her extensive work in ALS research. 2:50 Read the full coverage here: Source: Grossberg G, et al. Efficacy and safety of AXS-05 in Alzheimer's...
info_outlineMeeting Mic
In this episode of Meeting Mic, we bring you expert insights from the ASH Annual Meeting and Exhibition with a focus on leukemia, as well as Healio’s top headlines from the meeting. Aaron T. Gerds, MD, MS, discusses how socioeconomic disparities affect access to allogeneic hematopoietic stem cell transplantation for people with acute myeloid leukemia. :24 Hua Zhang, MD, PhD, reviews findings of bicistronic chimeric antigen receptor T-cell therapy induced durable response for most children with relapsed or refractory B-lineage acute lymphoblastic leukemia. 6:29 Moath Albliwi, MD,...
info_outlineMeeting Mic
In this episode of Meeting Mic, we bring you the highlights and insights from the San Antonio Breast Cancer Symposium 2024, as well as Healio’s top headlines from the meeting. Judy Garber, MD, MPH, chief of the division of cancer genetics and prevention at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School, reviews results of the OlympiA trial. :25 Raza Hoda, MD, a pathologist at Cleveland Clinic and assistant professor of pathology at Cleveland Clinic Lerner College of Medicine, discusses results from the DESTINY-Breast04 and DESTINY-Breast06 trials. 1:55...
info_outlineMeeting Mic
In this episode of Meeting Mic, we bring you expert insights from the ASH Annual Meeting and Exhibition, as well as Healio’s top headlines from the meeting. Gwen L. Nichols, MD, reviews a panel discussion on how hematologists and oncologists can best address patients’ concerns as AI’s role in medicine invariably expands. :24 Thomas G. Knight, MD, addresses financial toxicity for people with blood cancer. 6:29 Charles S. Abrams, MD, discusses results of the HIBISCUS trial and its implications for vaso-occlusive events. 16:30 Read the full coverage here: Disclosures: Abrams...
info_outlineMeeting Mic
In this episode of Meeting Mic, we bring you pearls and perspectives from the American Academy of Ophthalmology 2024 Meeting with a focus on AMD and retina. David A. Eichenbaum, MD, discusses results from a phase 1 trial investigating axitinib for the treatment of neovascular age-related macular degeneration. :28 Douglas Love discusses the company’s phase 3 program in geographic atrophy. 2:37 Pravin U. Dugel, MD, discusses the next steps for the phase 3 SOL-1 and SOL-R studies. 3:54 Jeremiah Brown, MS, MD, presents results from the phase 4 Elevatum trial investigating faricimab for diabetic...
info_outlineIn this episode of Meeting Mic, we bring you the highlights and insights from the San Antonio Breast Cancer Symposium 2024, as well as Healio’s top headlines from the meeting.
Judy Garber, MD, MPH, chief of the division of cancer genetics and prevention at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School, reviews results of the OlympiA trial. :25
Raza Hoda, MD, a pathologist at Cleveland Clinic and assistant professor of pathology at Cleveland Clinic Lerner College of Medicine, discusses results from the DESTINY-Breast04 and DESTINY-Breast06 trials. 1:55
Shimoli Barot, MD, medical oncologist at Cleveland Clinic Cancer Institute, examines the results of a study observing exceptional treatment response in patients with metastatic breast cancer. 6:02
Eleonora Teplinsky further discusses results of the COMET trial. 10:38
Jennifer A. Ligibel discusses an overview analysis looking at the relationship between body mass index at the time of breast cancer diagnosis and distant recurrence. 19:27
Read the full coverage here:
VIDEO: OlympiA trial shows ‘continued benefit’ in breast cancer survival
VIDEO: Study investigates HER2-low, ultralow eligibility for trastuzumab deruxtecan
VIDEO: Study investigates exceptional treatment response in metastatic breast cancer
Active monitoring safe for some patients with low-risk ductal carcinoma in situ
Source: Hwang ES, et al. Abstract GS2-05. Presented at: San Antonio Breast Cancer Symposium; Dec. 10-13, 2024; San Antonio.
Terminated study’s ‘challenges’ may guide future trials of MRD-guided breast cancer therapy
Source: Turner N, et al. Abstract GS3-01. Presented at: San Antonio Breast Cancer Symposium; Dec. 10-13, 2024; San Antonio.
Obesity elevates risk for distant recurrence, mortality in early-stage breast cancer
Source: Pan H, et al. Abstract GS2-09. Presented at: San Antonio Breast Cancer Symposium; Dec. 10-13, 2024; San Antonio.
Disclosures:
Barot reports no relevant financial disclosures.
Garber reports no relevant financial disclosures.
Hoda reports no relevant financial disclosures.
Teplinsky reports no relevant financial disclosures.